| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Omnicell (NASDAQ:OMCL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.2, with a high estimate of $55.00 and a low estimate of $34.00. This upward trend is apparent, with the current average reflecting a 5.79% increase from the previous average price target of $38.00.
A comprehensive examination of how financial experts perceive Omnicell is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sean Wieland | Piper Sandler | Lowers | Overweight | $55.00 | $57.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $40.00 | $37.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $37.00 | $35.00 |
| Allen Lutz | B of A Securities | Raises | Neutral | $34.00 | $30.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Overweight | $35.00 | $31.00 |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Omnicell's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Omnicell analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Omnicell displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 4.98%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Omnicell's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Omnicell's ROE excels beyond industry benchmarks, reaching 0.45%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Omnicell's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.3, Omnicell adopts a prudent financial strategy, indicating a balanced approach to debt management.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: OMCL
